The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program
Related Resources
All Resources
post
Understanding the FDA’s Evolving Expectations for Biopharma Compliance
Read More
post
CMC Considerations for Biotech Startups Entering Clinical Trials
Read More
case-study
From Data to Dossier: Smart Scale-Up Solutions in Biopharmaceutical Manufacturing
Read More
infographic
Cracking the Code: Syner-G’s Blueprint for Success with Pharmaceutical Stability Studies
Read More
Let's move from science to success.
Let’s Talk